Vaccine Adjuvants Market – By Product Type, By Route of Administration, By Disease Type, By Application, Global Forecast, 2025 to 2034

Vaccine Adjuvants Market Size

The global vaccine adjuvants market size was valued at around USD 1.3 billion in 2024 and is estimated to grow at 6.5% CAGR from 2025 to 2034. Vaccine adjuvants are substances added to vaccines to enhance the body's immune response to the antigen. They improve vaccine efficacy by stimulating the immune system, ensuring a stronger and longer-lasting immune response. Adjuvants can reduce the amount of antigen needed in a vaccine, making it more cost-effective and efficient.
 

The rising incidence of cervical cancer and infectious diseases such as human papillomavirus (HPV), HIV, tuberculosis, and other severe illnesses is anticipated to significantly drive the demand for vaccine adjuvants. According to the American Cancer Society, cervical cancer ranks as the fourth most common cancer among women worldwide, with an estimated 13,820 new cases and 4,360 deaths projected in 2024. This alarming incidence rate underscores the urgent need for effective vaccines and adjuvants to combat these diseases.
 

In addition, the increasing emphasis on achieving long-lasting immunity against both existing and emerging diseases is likely to further boost the demand for adjuvants. The Centers for Disease Control and Prevention (CDC) indicates that adjuvants are incorporated into certain vaccines to enhance the immune response, allowing for a reduction in the amount of antigen needed or the number of doses required. This efficiency could lead to a higher adoption rate of adjuvanted vaccines.
 

Vaccine Adjuvants Market Trends

• The significance of adjuvant research has grown considerably due to the limited immunogenicity of new vaccine antigens. The National Institutes of Health (NIH) has stressed the importance of developing adjuvants to improve vaccine efficacy, especially for populations with weakened immune systems, such as the elderly and immunocompromised individuals. This focus on research is expected to drive advancements in adjuvant technology.
   
• Furthermore, the increasing utilization of recombinant and synthetic vaccines is anticipated to accelerate the growth of the adjuvant market in the upcoming years.
   
• The WHO’s Global Vaccine Action Plan highlights the necessity of developing new and improved vaccines, including those utilizing recombinant technology. As these advanced vaccines frequently require adjuvants to enhance their effectiveness, their rising adoption is likely to further fuel the demand for adjuvants in vaccine formulations.
   

Vaccine Adjuvants Market Analysis

Based on product type, the market is divided into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other product types. The particulate adjuvants segment dominated the market accounting for 35.4% of revenue share in 2024.
 

• The increasing prevalence of infectious diseases has created a growing need for vaccines with improved efficacy. According to the World Health Organization (WHO), infectious diseases cause over 17 million deaths annually worldwide.
   
• Particulate adjuvants have demonstrated significant enhancement of immune responses, making them valuable components in vaccine formulations. This underscores the potential of particulate adjuvants in addressing global health challenges.
   
• Additionally, progress in nanotechnology-based drug delivery and materials science has facilitated the development of novel particulate adjuvants. These adjuvants can effectively encapsulate antigens and enhance their delivery to immune cells, driving increased interest in their application for vaccine development.
   

Based on route of administration, the vaccine adjuvants market is segmented into intramuscular, subcutaneous, oral, and other routes of administration. The intramuscular segment accounted for a 59.3% market share in 2024 and is projected for significant growth to reach USD 1.4 billion by 2034.
 

• Vaccines that induce strong and durable immune responses are essential, particularly for populations at higher risk of infectious diseases. Intramuscularly administered vaccine adjuvants significantly boost immune responses, enhancing vaccine effectiveness. This improved efficacy is crucial for protecting vulnerable populations against various infectious diseases.
   
• Furthermore, the global effort to increase vaccination rates, especially in the wake of the COVID-19 pandemic, has driven demand for effective vaccine formulations.
   
• The Centers for Disease Control and Prevention (CDC) reported that COVID-19 vaccination prevented an estimated 19.8 million deaths globally in the first year of vaccine rollout. Intramuscular administration with adjuvants improved vaccine efficacy, making it a preferred method for many public health programs. This approach has been instrumental in achieving higher immunization rates and better protection against infectious diseases worldwide.
   

Based on disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and other diseases. The infectious diseases segment dominated the market with the largest revenue of USD 909.3 million in 2024.
 

• The growing incidence of infectious diseases, including viral, bacterial, and parasitic infections, is driving the demand for effective vaccines. The need for improved vaccination strategies against diseases such as COVID-19, influenza, tuberculosis (TB), and emerging pathogens has increased interest in adjuvant use.
   
• The WHO reported that in 2023, approximately 10.8 million individuals worldwide were diagnosed with TB, which included 6 million men, 3.6 million women, and 1.3 million children. This underscores the critical role of effective vaccines in public health.
   
• Additionally, technological advancements in adjuvant formulation, including the development of novel adjuvants like liposomes, nanoparticles, and other particulate systems, are improving vaccine effectiveness. The WHO's Global Vaccine Action Plan 2011-2020 emphasized the importance of research and development in new vaccine technologies, including adjuvants, to enhance vaccine efficacy. These innovations enable customized immune responses, making them particularly relevant for vaccines targeting infectious diseases.
   

• The U.S. vaccine adjuvants market is projected to grow significantly, reaching USD 927.5 million by 2034.
   
• The U.S. government, through agencies such as the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), is investing in vaccine research and public health initiatives. These efforts primarily focus on developing and improving adjuvants to enhance vaccine efficacy against infectious diseases.
   
• Additionally, collaborations between pharmaceutical companies, research institutions, and universities in the U.S. are advancing innovation in vaccine adjuvant research. These partnerships are essential for developing new adjuvant technologies and improving existing formulations. For example, in February 2024, TollereBio announced a partnership with the University of Maryland, Baltimore (UMB) for the worldwide license of a novel vaccine adjuvant technology. The UMB spinout aimed to commercialize the patented bacterial enzymatic combinatorial chemistry (BECC) platform to develop accessible and cost-effective vaccine adjuvants for both prophylactic and therapeutic vaccines.
   

The vaccine adjuvants market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The COVID-19 pandemic underscored the critical role of vaccines in public health. For instance, as of November 2023, the NHS in England reported administering a total of 11,404,669 COVID vaccinations and 16,190,661 flu vaccinations. This has led to an increased focus on developing effective vaccines against both existing and emerging infectious diseases, driving greater interest in adjuvants that can enhance vaccine efficacy.
   
• UK has implemented comprehensive immunization programs to protect vulnerable populations. The National Health Service (NHS) reports that in 2021-2022, 89.2% of children in England had received their first dose of the MMR, showcasing the effectiveness of established vaccination programs.
   
• Continuous enhancement of these programs through the incorporation of effective adjuvants is crucial for achieving higher vaccination rates and improving overall public health outcomes. The UK's commitment to vaccine research and development positions it as a leader in advancing immunization strategies.
   

Japan vaccine adjuvants market is anticipated to witness lucrative growth between 2025 to 2034.
 

• In 2023, the average life expectancy in Japan was 87.14 years for women and 81.09 years for men, ranking among the highest globally according to the World Health Organization (WHO). This longevity has led to a rapidly aging population, with 29.1% of Japanese citizens aged 65 or older in 2023, as reported by the BBC.
   
• This aging demographic drives the demand for vaccines that effectively protect elderly individuals with weakened immune systems. Adjuvants play a crucial role in enhancing vaccine efficacy, making them essential for immunizing older adults against infectious diseases.
   

The vaccine adjuvants market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is experiencing an increasing incidence of infectious diseases, including hepatitis, influenza, and other vaccine-preventable illnesses. According to the National Institutes of Health, from 2006 to 2021, a total of 61,425 acute hepatitis B cases were reported among Saudi nationals, averaging 3,839 cases per year, highlighting the challenge of infectious diseases. This growing disease burden necessitates the development of effective vaccines, consequently driving the demand for adjuvants to enhance vaccine efficacy and safety. The need for improved vaccines is likely to boost the adjuvant market in Saudi Arabia.
   
• Additionally, the Saudi healthcare system is prioritizing preventive healthcare measures, with a focus on vaccination campaigns. This emphasis is propelling the development of adjuvanted vaccines to improve immunization rates and achieve better health outcomes across the population. As a result, the demand for vaccine adjuvants in Saudi Arabia is expected to grow in line with these preventive healthcare initiatives.
   

Vaccine Adjuvants Market Share

The market is competitive, featuring both major global companies and numerous smaller firms. A key strategy for participants is investing in the development of advanced vaccine adjuvant technologies, such as nanoparticle-based adjuvants, toll-like receptor (TLR) agonists, and virus-like particle (VLP) adjuvants, to enhance accuracy and efficiency. Strategic partnerships with research institutions and healthcare providers are crucial for integrating innovative technologies and expanding distribution, enabling companies to address the rising demand for non-invasive and cost-effective diagnostic solutions. Regulatory support and streamlined approval processes further drive innovation and market entry, solidifying the position of firms within the growing market.
 

Vaccine Adjuvants Market Companies

Some of the eminent market participants operating in the vaccine adjuvants industry include:

• Agenus
• Allergy Therapeutics
• Aurorium
• Brenntag Biosector
• Croda International
• CSL Limited
• Dynavax Technologies Corporation
• EuBiologics
• GSK plc
• Merck KGaA
• Novavax
• OZ Biosciences
• Riboxx GmbH
• Seppic
• SPI Pharma
   

Vaccine Adjuvants Industry News:

• In October 2024, SPI Pharma, Inc., a global leader in biopharmaceutical excipients and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in innate immune modulators, announced a partnership to launch two adjuvant systems. The partners unveiled these innovative adjuvant systems at the World Vaccines Congress Europe. This collaboration highlighted SPI Pharma and Inimmune’s commitment to advancing vaccine technology and strengthening their presence in the immunology space.
   
• In March 2024, Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) entered into a partnership agreement focused on innovating and developing adjuvant formulations. Through this agreement, Croda and AAHI combined their expertise to make novel vaccine adjuvant formulations accessible worldwide, supporting the creation of next-generation, robust, and long-lasting vaccines. This alliance underscored both organizations' dedication to improving global health through advanced vaccine solutions.
   

Vaccine Adjuvants Market Companies

Some of the eminent market participants operating in the vaccine adjuvants industry include:

• Agenus
• Allergy Therapeutics
• Aurorium
• Brenntag Biosector
• Croda International
• CSL Limited
• Dynavax Technologies Corporation
• EuBiologics
• GSK plc
• Merck KGaA
• Novavax
• OZ Biosciences
• Riboxx GmbH
• Seppic
• SPI Pharma
   

The vaccine adjuvants market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Adjuvant emulsions
• Pathogen components
• Saponin-based adjuvants
• Particulate adjuvants
• Other product types

Market, By Route of Administration

• Intramuscular
• Subcutaneous
• Oral
• Other routes of administration

Market, By Disease Type

• Infectious diseases
• Cancer
• Other diseases

Market, By Application

• Human vaccines
• Veterinary vaccines

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE